On Invalid Date, Qualigen Therapeutics (NASDAQ: QLGN) reported Q3 2023 earnings per share (EPS) of -$0.72, up 25.77% year over year. Total Qualigen Therapeutics earnings for the quarter were -$3.66 million. In the same quarter last year, Qualigen Therapeutics's earnings per share (EPS) was -$0.97.
As of Q1 2024, Qualigen Therapeutics's earnings has grown year over year. Qualigen Therapeutics's earnings in the past year totalled -$17.34 million.
What is QLGN's earnings date?
Qualigen Therapeutics's earnings date is Invalid Date. Add QLGN to your watchlist to be reminded of QLGN's next earnings announcement.
What was QLGN's revenue last quarter?
On Invalid Date, Qualigen Therapeutics (NASDAQ: QLGN) reported Q3 2023 revenue of $0.00 up N/A year over year. In the same quarter last year, Qualigen Therapeutics's revenue was $0.00.
What was QLGN's revenue growth in the past year?
As of Q1 2024, Qualigen Therapeutics's revenue has grown 27.25% year over year. This is 142.04 percentage points lower than the US Biotechnology industry revenue growth rate of 169.3%. Qualigen Therapeutics's revenue in the past year totalled $4.62 million.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.